What drives the AYA.AX stock price today?

Today the AYA.AX stock price moves on earnings outlook, product adoption signals for Salix, and technical selling. Key visible drivers are EPS **-0.18**, intraday volume **865,338**, and market reaction to valuation metrics.

What is Meyka AI’s view on AYA.AX stock?

Meyka AI rates AYA.AX **C+** with a score **59.22** and a HOLD suggestion. The model projects **A$6.67** yearly, implying **+59.57%**, but notes forecasts are projections and not guarantees.

Are there clear valuation concerns for AYA.AX stock?

Yes. Valuation shows P/B **20.52** and price-to-sales near **17,159.89**, which exceed typical healthcare peers. Those metrics reflect low current revenue and high investor expectations.

When are Artrya’s next earnings or announcements relevant to AYA.AX stock?

Artrya’s next earnings announcement is scheduled for **24 Feb 2026**. Material contract wins or regulatory updates ahead of that date could move the AYA.AX stock significantly.

AU Stocks

A$4.18 Artrya Limited (AYA.AX) ASX pre-market 15 Jan 2026: 59.57% model upside

ByDanny Kontos January 15, 2026January 15, 2026

The AYA.AX stock opens pre-market at A$4.18, down 6.28% from yesterday as traders digest valuation and AI adoption signals. Artrya Limited (AYA.AX) on the ASX uses AI for coronary disease detection with its Salix platform. We provide a focused AYA.AX stock analysis, linking price drivers, technical signals and Meyka AI forecast for investors watching AI healthcare names.